Key Points - The company has established a special account for raised funds and signed tripartite and quadripartite supervision agreements to ensure proper management and usage of the funds [2][3][5] - The total amount raised from the public offering was RMB 693,516,251.67 after deducting issuance costs, with 21,780,000 shares issued at a price of RMB 35.76 per share [1] - The company plans to temporarily use up to RMB 150 million of idle raised funds to supplement working capital, with a usage period not exceeding 12 months [2][3] - The special accounts have been opened at China Merchants Bank, with specific account numbers designated for the company and its subsidiary [3][8] - The tripartite supervision agreement involves the company, the bank, and the sponsor, ensuring that the funds are used solely for their intended purpose and are subject to regular oversight [5][6] - The quadripartite supervision agreement includes the company, its subsidiary, the bank, and the sponsor, reinforcing the management and protection of investor rights [7][8]

证券代码：688677 证券简称：海泰新光 公告编号：2025-042 青岛海泰新光科技股份有限公司 关于增设募集资金专项账户并签订 募集资金三方和四方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2021 年 1 月 12 日出具的《关于同意青岛海泰新光科技股份有限公司首次公开发行股票注册 的批复》（证监许可[2021]90 号），公司获准向社会公开发行人民币普通股（A） 股 21,780,000.00 股，发行价格为 35.76 元/股，募集资金总额为人民币 778,852,800.00 元，扣减承销费（不含增值税）人民币 61,529,371.20 元，以 及其他发行费用（不含增值税）人民币 23,807,177.13 元后，募集资金净额为 人民币 693,516,251.67 元。上述资金到位情况经安永华明会计师事务所（特殊 普通合伙）验证，并出具安永华明（2021 验字第 61544479_J03 号）《验资报 告》。 为 ...

8月4日，海泰新光今日收盘45.65元，上涨7.39%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到38.11倍，创293天以来新低，总市值54.72亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.32倍，行业中值38.11倍，海泰新光排 名第76位。 股东方面，截至2025年3月31日，海泰新光股东户数4446户，较上次增加580户，户均持股市值35.28万 元，户均持股数量2.76万股。 青岛海泰新光科技股份有限公司的主营业务是医用内窥镜器械和光学产品的研发、制造、销售和服务。 公司的主要产品是4K荧光/白光腹腔镜、内窥镜光源模组、摄像适配器/适配镜头等。 最新一期业绩显示，2025年一季报，公司实现营业收入1.47亿元，同比24.86%；净利润4668.87万元， 同比21.45%，销售毛利率64.98%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13海泰新光38.1140.434.0754.72亿行业平均 54.3250.504.72116.17亿行业中值38.1137.682.7056.52亿1九安医疗10.9911.120.87185.49亿2新华 ...

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is experiencing significant growth in its medical device segment, particularly in high-performance endoscope products, benefiting from the depreciation of the RMB and its recognition as a "specialized, refined, distinctive, and innovative" enterprise [2][3]. Company Overview - Qindao Haitai New Light was established on June 11, 2003, and went public on February 26, 2021. Its main business involves the research, development, production, and sales of medical endoscope devices and optical products [7]. - The revenue composition of the company is as follows: 77.94% from medical endoscope devices, 21.55% from optical products, and 0.51% from other sources [7]. Financial Performance - For the first quarter of 2025, the company achieved a revenue of 147 million yuan, representing a year-on-year growth of 24.86%, and a net profit attributable to shareholders of 46.69 million yuan, up 21.45% year-on-year [7]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. Market Position and Recognition - The company has a 69.12% share of overseas revenue, benefiting from the depreciation of the RMB [3]. - It has been recognized as a "specialized, refined, distinctive, and innovative" enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating strong innovation capabilities and market share [3]. Stock Performance - On August 4, the stock price of Haitai New Light increased by 7.39%, with a trading volume of 203 million yuan and a market capitalization of 5.472 billion yuan [1]. - The average trading cost of the stock is 38.17 yuan, with the stock currently near a resistance level of 45.73 yuan, indicating potential for upward movement if this level is breached [6].

Core Viewpoint - Qingdao Haitai Newlight Technology Co., Ltd. plans to temporarily use idle raised funds not exceeding RMB 150 million to supplement working capital, which will be used solely for business expansion and daily operations related to its main business [2][7][8]. Group 1: Announcement of Fund Usage - The company held its fourth board meeting and supervisory board meeting on August 1, 2025, where it approved the proposal to use idle raised funds for working capital [2][8]. - The usage period for the funds is valid for 12 months from the date of board approval, and the amount can be rolled over within this period [2][7]. Group 2: Fundraising Background - The company successfully raised a total of RMB 778.85 million through the issuance of 21,780,000 shares at a price of RMB 35.76 per share, with a net amount of RMB 693.52 million after deducting underwriting fees and other expenses [3][4]. - The raised funds were deposited into a special account for management and usage, with agreements signed with relevant parties to ensure proper oversight [4]. Group 3: Fund Investment Projects - The company has completed several fundraising projects, including the construction of an endoscope system production base and a research and experimental center, which were concluded by December 2023 [5][6]. - The company has also approved extensions and adjustments to the timelines and implementation entities for certain fundraising projects [6]. Group 4: Supervisory Board Opinions - The supervisory board agrees that the proposed use of idle funds does not change the intended use of the raised funds and will not affect the normal progress of investment projects [9][14]. - The board confirmed that the funds will only be used for daily operations related to the main business and will not harm the interests of the company and its shareholders [9][14].

关于使用部分闲置募集资金暂时补充流动资金的公告 证券代码：688677 证券简称：海泰新光 公告编号：2025-039 青岛海泰新光科技股份有限公司 ●使用期限自公司董事会审议通过之日起 12 个月内有效，在有效期内上述 额度可以滚动循环使用，且公司将随时根据募投项目的进展及需求情况及时归还 至募集资金专用账户。 ●本议案无需提交公司股东大会审议。保荐机构国泰海通证券股份有限公司 对本事项出具了明确同意的核查意见。 一、募集资金基本情况 经上海证券交易所科创板股票上市委员会 2020 年 9 月 29 日审核同意，并经 中国证券监督管理委员会 2021 年 1 月 12 日《关于同意青岛海泰新光科技股份有 限公司首次公开发行股票注册的批复》（证监许可[2021]90 号）核准，同意本 公司公开发行人民币普通股 21,780,000 股，发行价格为人民币 35.76 元/股。募 集资金总额为人民币 778,852,800.00 元，扣减承销费（不含增值税）人民币 后 ， 募 集 资 金 净 额 为 人 民 币 693,516,251.67 元 。 实 际 到 账 金 额 人 民 币 募集资金于 2021 年 2 ...

（文章来源：证券日报） 证券日报网讯 8月1日晚间，海泰新光发布公告称，截至2025年7月31日，青岛海泰新光科技股份有限公 司通过上海证券交易所交易系统以集中竞价交易方式回购公司股份1，387，000股，占公司总股本119， 877，000股的比例为1.15770%。 ...

证券日报网讯 8月1日晚间，海泰新光发布公告称，公司第四届监事会第五次会议审议通过了《关于使 用部分闲置募集资金暂时补充流动资金的公告》。 （文章来源：证券日报） ...

格隆汇8月1日丨海泰新光(688677.SH)公布，公司于2025年8月1日召开第四届董事会第五次会议及第四 届监事会第五次会议，审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议案》，同意公司 使用闲置募集资金不超过人民币15,000万元（含本数）暂时补充流动资金，并仅用于公司的业务拓展、 日常经营等与主营业务相关的生产经营活动。 ...

二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间，应当在每个月的前 3 个交易日 内公告截至上月末的回购进展情况，现将公司回购股份的进展公告如下： 证券代码：688677 证券简称：海泰新光 公告编号：2025-041 青岛海泰新光科技股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/3/5 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 日~2026 年 3 3 | 2025 3 | 月 | 2 | 日 | | 预计回购金额 | 万元 万元~10,000 | 5,000 | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 累计已回购股数 | ...